Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Sales 2024 * | 210K 16.76M | Sales 2025 * | 300K 23.95M | Capitalization | 13.09M 1.04B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.84B | Net income 2025 * | -28M -2.24B | EV / Sales 2024 * | 62.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 43.6 x |
P/E ratio 2024 * |
-0.72
x | P/E ratio 2025 * |
-0.75
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.1% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 18/01/15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 31/08/13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 30/06/15 |
Jack Stover
BRD | Director/Board Member | 69 | 22/05/16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 31/03/20 |
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |